NT_1170x120_1-11-18

Echosens

Noninvasive exams can help head off liver disease

Noninvasive exams can help head off liver disease

A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH). The main risk factors for fatty liver disease include a sedentary

Diabetes increases risk for liver disease

Diabetes increases risk for liver disease

Nonalcoholic fatty liver disease (NAFLD) is an asymptomatic disease that affects about 100 million Americans. Being overweight, obese or diabetic are primary risk factors for NAFLD, an umbrella term describing those liver diseases that aren’t related to alcohol consumption. Whereas consumption of too much alcohol over a period of several years is known to damage